Clinical Trials Browser

Phase 1 × Withdrawn × Prostatic Neoplasms × Clear all

NCT03477864 2025-04-29

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT02921373 2024-07-24

TRACK

Phase 1 Withdrawn

Prostatic Neoplasms

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Prostatic Neoplasms

NCT01826838 2022-02-24

BrUOGPR255

Phase 1 Withdrawn

Prostatic Neoplasms

NCT04296578 2021-08-12

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Phase 1 Withdrawn

Prostatic Neoplasms

NCT03110588 2020-10-19

Phase I Trial of PACE for Metastatic Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT02647983 2020-01-22

Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection

Phase 1 Withdrawn

Prostatic Neoplasms

NCT02182622 2019-06-19

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

Phase 1 Withdrawn

Prostatic Neoplasms

NCT03465345 2018-08-03

Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Phase 1 Withdrawn

Prostatic Neoplasms

NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT02396368 2015-11-20

Radium-223

Phase 1 Withdrawn

Prostatic Neoplasms

NCT01685489 2015-10-27

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

Phase 1 Withdrawn

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01163448 2015-03-06

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT01320787 2014-10-23

18-F-Fluoroacetate as PET Imaging Agent

Phase 1 Withdrawn

BreastCNSGenitourinary

Brain Neoplasms, Breast Neoplasms, Prostatic Neoplasms, Central Nervous System Neoplasms

NCT01981668 2014-03-19

The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation

Phase 1 Withdrawn

Prostatic Neoplasms

NCT00110526 2013-10-24

Gene Therapy for Prostate Cancer That Returns After Radiation Therapy

Phase 1 Withdrawn

Neoplasm Recurrence, Local, Prostatic Neoplasms

NCT01197209 2013-08-23

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

Phase 1 Withdrawn

Neoplasms, Prostatic Neoplasms

NCT00691977 2013-04-24

Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate

Phase 1 Withdrawn

Prostatic Neoplasms

NCT00005827 2012-04-24

Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms